Eliem Therapeutics Past Performance
How has Eliem Therapeutics performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
16.2%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ELYM is currently unprofitable.
Growing Profit Margin: ELYM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ELYM's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ELYM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ELYM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (53%).
Return on Equity
High ROE: ELYM has a negative Return on Equity (-35.75%), as it is currently unprofitable.